Patients with pancreatic cancer experience measurable changes in body composition years before diagnosis that differ from those seen in similar individuals without cancer.
Related to this article
The FDA granted fast track designation to MC001 for pancreatic cancer.
The FDA expands nogapendekin alfa inbakicept in bladder cancer, European regulators back daraxonrasib in pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The EMA's CHMP recommended approval of daraxonrasib for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.
VS-7375 produced a responses previously treated metastatic pancreatic ductal adenocarcinoma.
The resubmission follows a third complete response letter issued in July 2026 that cited manufacturing deficiencies rather than efficacy or safety concerns.
The FDA has granted fast track designation to opamtistomig for first-line treatment of advanced or metastatic biliary tract cancer.
Advertisement
Advertisement
Trending on OncLive
1
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
2
FDA Grants Orphan Drug Designation to Onvansertib for Chronic Myelomonocytic Leukemia
3
SBE303 Receives FDA Fast Track Designation in Pretreated Urothelial Cancer
4
Roginolisib Demonstrates Preliminary Activity in Metastatic Uveal Melanoma
5